News | February 16, 2024
Glenmark Pharma posts Q3 FY24 net loss of Rs. 331 Cr
he lower sales in the current quarter are mainly on account of a one?time impact on the company’s India business
he lower sales in the current quarter are mainly on account of a one?time impact on the company’s India business
Gross profit was Rs. 313.3 crore, up by +30.4% YoY with a Gross margin of 53.5%
The company's SaaS solutions are tailored to enhance accessibility, efficiency, and patient-centricity in healthcare operations
MASH is a chronic and progressive liver disease characterised by fat accumulation and inflammation in the liver,
The CDCCs are strategically positioned in regions identified as high-impact areas
The company is strongly committed to enhancing customer satisfaction and catering to the discerning needs of renowned pharmaceutical companies
The US FDA's clearance of the trial marks the first global registrational Phase III trial for olverembatinib in patients with CP-CML to be conducted.
Launches collaborative centre for translational research in head and neck cancer
The company is committed to a new category development in areas like adult Immunization with products like Shingrix to make a positive impact to the lives of the patients in India
These re-agent and diagnostic test kits come with 99.7% accuracy
Subscribe To Our Newsletter & Stay Updated
